Psoriasis
Explore original articles, case reports, and podcasts that focus on psoriasis.
International Dermatology Outcome Measures (IDEOM): Report from the 2021 Annual Meeting
August 2022 | Volume 21 | Issue 8 | Original Article | 867 | Copyright © August 2022
Background: International Dermatology Outcome Measures (IDEOM) is a non-profit organization founded in 2013. It is composed of researchers and stakeholders who work to develop evidenc...
Read MoreOnset of Plaque Psoriasis Treatment Responses With Anti-IL-17/IL-23 Biologic Therapies
August 2022 | Volume 21 | Issue 8 | Original Article | 854 | Copyright © August 2022
Background: The impact of psoriasis on quality of life arises from both physical symptoms, such as pain and pruritus, and the psychosocial effects of the often highly visible lesions....
Read MoreTreatment of Scalp Psoriasis
August 2022 | Volume 21 | Issue 8 | Original Article | 833 | Copyright © August 2022
Scalp involvement is seen in a majority of individuals with psoriasis, a chronic autoimmune skin disease with variable phenotypes. Occasionally, isolated scalp involvement is observed; and this causes...
Read More"I'm Off My Meds": Public Perception of Interactions Between SARS-CoV-2 Vaccines and Anti-Psoriatic Treatments Online
August 2022 | Volume 21 | Issue 8 | Features | 901 | Copyright © August 2022
Importance: Psoriasis patients may seek information about the SARS-CoV-2 vaccine and their diagnosis from social media platforms. Analyses of social media interactions may help guide dermatologists&rs...
Read MorePediatric Verrucous Psoriasis: A Case Report in a Pediatric Patient and Discussion of the Literature
August 2022 | Volume 21 | Issue 8 | Case Reports | 891 | Copyright © August 2022
Verrucous psoriasis (VP) is a rare histologic variant of psoriasis. To date, fewer than 40 cases have been reported, with pediatric cases representing an exceedingly small fraction. Treatment options ...
Read MoreSingle-Centre Real-Life Experience of Guselkumab in Patients with Moderate-to-Severe Plaque Psoriasis
August 2022 | Volume 21 | Issue 8 | Original Article | 864 | Copyright © August 2022
The efficacy of guselkumab has been demonstrated in randomized controlled trials, but real-life data are still missing. This study presents a single-center real-life experience in treating moderate-to...
Read MoreNail Psoriasis Improvement During Tildrakizumab Therapy: A Real-Life Experience
August 2022 | Volume 21 | Issue 8 | Editorials | 914 | Copyright © August 2022
The aim of this retrospective study of patients affected by plaque psoriasis who underwent tildrakizumab therapy was to describe and compare the response of the nail psoriasis and the plaque psoriasis...
Read MoreSystematic Review of Lichen Planus Pigmentosus in Children
August 2022 | Volume 21 | Issue 8 | Original Article | 850 | Copyright © August 2022
Background: Pediatric lichen planus (LP) is a relatively uncommon condition, with increased presentation in children with darkly pigmented skin.
Objective: To u...
Read MoreSubgroup Analyses by European Country-Specific Reimbursement Requirements Confirm Efficacy for Ixekizumab in Psoriasis
June 2022 | Volume 21 | Issue 6 | Original Article | 659 | Copyright © June 2022
Background: Biologic drugs are generally recommended for treating moderate-to-severe psoriasis. While eligibility criteria are primarily defined by clinical treatment guidelines, acce...
Read MoreProbiotics Supplementation Improves Quality of Life, Clinical Symptoms, and Inflammatory Status in Patients With Psoriasis
June 2022 | Volume 21 | Issue 6 | Original Article | 637 | Copyright © June 2022
Background: Studies have proposed a link between psoriasis and imbalanced gut microbiome. Therefore, the modulation of the gut microbiota with probiotics may improve clinical outcomes...
Read MoreThe Use of Bakuchiol in Dermatology: A Review of In Vitro and In Vivo Evidence
June 2022 | Volume 21 | Issue 6 | Original Article | 624 | Copyright © June 2022
The plant Psoralea corylfolia contains compounds such as psoralens that are useful for the treatment of psoriasis and vitiligo, and the plant is used in Chinese and Indian traditional medicin...
Read MoreEvidence Threshold for a Precision Medicine Test that Predicts Optimal Response to a Biologic Agent in Patients With Psoriasis: A Consensus Panel
June 2022 | Volume 21 | Issue 6 | Original Article | 630 | Copyright © June 2022
Precision medicine approaches are receiving increased attention in dermatology, including inflammatory skin diseases. In psoriasis, a precision medicine treatment paradigm could temper the rapid incre...
Read MoreThe Maintenance Effect of Calcipotriene 0.05% and Betamethasone Dipropionate 0.064% (Cal/BD) Aerosol Foam in Combination With Apremilast
April 2022 | Volume 21 | Issue 4 | Original Article | 381 | Copyright © April 2022
Even in light of significant recent therapeutic advancements, many patients with psoriasis will use a combination of treatments at some point in the disease course. Despite the frequency with which co...
Read MoreLong-Term Treatment Patterns Among Patients With Psoriasis Treated With Ixekizumab or Adalimumab: A Real-World Study
April 2022 | Volume 21 | Issue 4 | Original Article | 399 | Copyright © April 2022
Background: There is a paucity of long-term real-world evidence comparing the effectiveness of ixekizumab (IXE) and adalimumab (ADA). We compared real-world treatment patterns of IXE-...
Read MoreLong-Term Skin Clearance With Brodalumab in Patients With Psoriasis and Inadequate Response to Prior Biologics
April 2022 | Volume 21 | Issue 4 | Original Article | 364 | Copyright © April 2022
Background: Despite the emergence of multiple biologic drug options for psoriasis, unmet treatment needs remain. Biologic therapies can vary in their effectiveness and adverse events,...
Read MoreA Case of Late-Onset Alopecia Areata
April 2022 | Volume 21 | Issue 4 | Case Reports | 420 | Copyright © April 2022
Alopecia areata (AA) is a condition characterized by nonscarring hair loss. Cases of alopecia areata are most commonly seen in patients under age 30 and are frequently idiopathic. In this report, we d...
Read MorePustular and Erythrodermic Psoriasis in Patients Treated With Oral Glucocorticoids: A Survey of United States Dermatologists
April 2022 | Volume 21 | Issue 4 | Features | 427 | Copyright © April 2022
Dermatology dogma has cautioned against the use of orally administered glucocorticoids (OAG) in the treatment of psoriasis, largely due to concerns of life-threatening generalized pustular psoriasis (...
Read MorePooled Analysis Demonstrating Superior Patient- Reported Psoriasis Treatment Outcomes for Calcipotriene/ Betamethasone Dipropionate Cream Versus Suspension/Gel
March 2022 | Volume 21 | Issue 3 | Original Article | 242 | Copyright © March 2022
Background: Calcipotriene and betamethasone dipropionate (CAL/BDP) cream is a novel treatment of plaque psoriasis based on PAD™ Technology (PAD-cream) designed to improve patien...
Read MorePustular Psoriasis Appearing Induced by Dupilumab Therapy in a Patient With Atopic Dermatitis
March 2022 | Volume 21 | Issue 3 | Case Reports | 311 | Copyright © March 2022
Dupilumab inhibits T-helper 2 (Th2)-driven inflammation cascade by blocking interleukin-4 (IL-4) and IL-13 signaling, which has been recognized to play a crucial role in the pathogenesis of atopic der...
Read MoreAdjunctive Use of Calcipotriene 0.005%/Betamethasone Dipropionate 0.064% Foam in Patients With Psoriasis Treated With Ixekizumab
March 2022 | Volume 21 | Issue 3 | Original Article | 235 | Copyright © March 2022
Objective: To examine the effectiveness and safety of adjunctive treatment with calcipotriene 0.005%/betamethasone dipropionate 0.064% (Cal/BD) foam in adult patients with chronic pla...
Read More